Novo Nordisk A/S buy mnake
Start price
19.03.13
/
50%
€25.99
Target price
19.09.13
€28.80
Performance (%)
0.40%
End price
19.09.13
€25.61
Summary
This prediction ended on 19.09.13 with a price of €25.61. During the runtime of the prediction for Novo Nordisk A/S the price only changed by 0.40%. mnake has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novo Nordisk A/S | - | - | - | - |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
Comments by mnake for this prediction
In the thread Novo Nordisk A/S diskutieren
kurzfristig Rückschläge - langfristig klar Wachstum
Die Aktie wir immer wieder Rückschläge erleiden, die Wachstumsphase wird langfristig anhalten
(Laufzeit überschritten)
Stopped prediction by mnake for Novo Nordisk A/S
Novo Nordisk A/S
Start price
Target price
Perf. (%)
€41.28
12.08.16
12.08.16
€49.00
11.11.16
11.11.16
-25.23%
11.11.16
11.11.16
